Toulouse Onco Week 2025

1. Programme
2. Company and technology pitches
Company and technology pitches
This session will highlight disruptive solutions, cutting-edge technologies and innovative approaches that are transforming the way we approach cancer research, diagnosis and treatment.
8 companies will have the opportunity to share their innovative projects with you, with the aim of fostering collaboration and innovation in oncology.

Come and discover these companies that are shaping the future of oncology and opening up new perspectives for patients and healthcare professionals.

Represented companies:

1.		G.CLIPS biotech changes paradigm on targets and drug discovery particularly in cancer and immunology. We have developed a unique platform that enables target and drug candidate generation, profiling, and optimization of lead-like therapeutics. Our focus is on targeting both membrane and soluble proteins within their pathology-like environments.
2.
3.		"At Nikaia we are developing a first-in-class NIK degrader. Targeting NIK, a key regulator of the non-canonical NF-κB pathway, holds immense therapeutic potential for treating cancer and managing autoimmune diseases."
4.		Persea is developping a cell and gene therapy changing the game against liver cancers.
5.		Magic Genomix develops a cutting-edge clinical decision support software powered by genomic instability analysis to enhance personalized medicine in oncology.
6.		StromaCare is revolutionising the treatment of cancer by developing STRO-501, a unique antibody specifically targeting the BIGH3 protein, which is ubiquitous in tumours. By neutralising this protein, STRO-501 considerably boosts the efficacy of immunotherapies, offering a new weapon against the most resistant cancers.
7.		Okomera is a start-up incorporated in Paris in 2020 that develops droplet microfluidics & AI solutions for tumoroid screening in drug discovery.
8.		See2cure detects the invisible to improve surgery and reduce recurrence of abdominal adenocarcinoma using a targeted fluorescent guidance innovation.